Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All zinc studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19

Jul 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 34% Improvement Relative Risk Zinc for COVID-19  Yao et al.  LATE TREATMENT Is late treatment with zinc beneficial for COVID-19? Retrospective 242 patients in the USA Lower mortality with zinc (not stat. sig., p=0.09) c19early.org Yao et al., Chest, July 2020 Favorszinc Favorscontrol 0 0.5 1 1.5 2+
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020
 
*, now with p = 0.00000032 from 46 studies, recognized in 17 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,800+ studies for 98 treatments. c19early.org
Retrospective 242 hospitalized patients in the USA showing adjusted hazard ratio for zinc treatment, aHR 0.66 [0.41-1.07].1 notes that the study would be more informative if baseline serum zinc levels were known.
Although the 34% lower mortality is not statistically significant, it is consistent with the significant 30% lower mortality [12‑44%] from meta analysis of the 21 mortality results to date.
risk of death, 34.0% lower, RR 0.66, p = 0.09, treatment 73 of 196 (37.2%), control 21 of 46 (45.7%), adjusted per study, multivariate Cox regression.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yao et al., 22 Jul 2020, retrospective, USA, peer-reviewed, 9 authors.
This PaperZincAll
Abstract: [ Chest Infections Research Letter ] The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19 An Observational Study To the Editor: Zinc is an investigational agent against coronavirus disease 2019 (COVID-19) and has known preventative and therapeutic roles in other infections.1-3 Zinc deficiency is associated with lower survival among older patients with pneumonia and predisposes to other viral infections.3 Established risk factors for critical COVID-19, including older age, diabetes mellitus, and cardiovascular disease, are also associated with zinc deficiency.2 The antiviral and immunomodulatory effects of zinc have made it a candidate against severe acute respiratory Methods In this single-institution retrospective study, we assessed the survival of hospitalized patients with COVID-19 treated with vs without zinc sulfate. This study was conducted in accordance with the amended Declaration of Helsinki. This study’s protocol was approved and was granted a waiver of informed consent by the hospital board on April 15, 2020, based on its retrospective design and the lack of identifying information to be published, collected, or analyzed. Data of all patients with COVID-19 (N ¼ 242) admitted at the Hoboken University Medical Center until April 11, 2020, were retrospectively collected on April 21, 2020. COVID-19 was confirmed in all patients using quantitative real-time reverse transcription polymerase chain reaction for SARS-CoV-2 RNA. Clinical severity was stratified based on World Health Organization8 guidelines according to clinical, radiographic, and laboratory information from the first 24 h of admission. The primary outcome was days from admission to inhospital mortality. Data for patients who did not meet the primary outcome were censored on April 21, 2020. Our primary analysis explored the causal association between zinc therapy and the survival of hospitalized patients with COVID-19. Inverse probability weighting (IPW) and a censorship model derived an effect estimate of zinc therapy on survival using the parameter defined as the Results Of 242 patients, 81.0% received zinc sulfate at a total daily dose of 440 mg (100 mg elemental zinc). The median age of patients who received zinc was 65 years (interquartile range, 53-77), whereas that of the control 108 Research Letter syndrome-coronavirus-2 (SARS-CoV-2) infection.2-4 Zinc may decrease the activity of the angiotensin converting enzyme 2, the receptor for SARS-CoV-2. Zinc T-cell modulation may downregulate the cytokine storm associated with severe COVID-19.2,4 These properties underlie the speculated efficacy of chloroquine, a zinc ionophore, and the derivative hydroxychloroquine, which are investigational agents in the worldwide World Health Organization SOLIDARITY trial.2,5,6 Furthermore, chloroquine may increase cellular zinc uptake, suggesting therapeutic benefit from the combination of the two agents.4 Despite zinc’s low risk of adverse effects, zinc’s role in the management of COVID-19 must be supported by clinical data.7 Therefore, we investigated the role of zinc among hospitalized patients with COVID-19. average treatment effect on the treated (ATET). The lack of sufficient overlap or the positive probability of assignment to each treatment level precluded the estimation of the average treatment effect. Multivariable logistic regression modeled the propensity to receive zinc by assigning weights to established predictors of mortality and..
{ 'indexed': {'date-parts': [[2024, 3, 31]], 'date-time': '2024-03-31T18:57:47Z', 'timestamp': 1711911467002}, 'reference-count': 7, 'publisher': 'Elsevier BV', 'issue': '1', 'license': [ { 'start': { 'date-parts': [[2021, 1, 1]], 'date-time': '2021-01-01T00:00:00Z', 'timestamp': 1609459200000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2022, 1, 6]], 'date-time': '2022-01-06T00:00:00Z', 'timestamp': 1641427200000}, 'content-version': 'am', 'delay-in-days': 370, 'URL': 'http://www.elsevier.com/open-access/userlicense/1.0/'}], 'content-domain': { 'domain': [ 'clinicalkey.fr', 'clinicalkey.jp', 'clinicalkey.com.au', 'clinicalkey.es', 'clinicalkey.com', 'journal.chestnet.org', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2021, 1]]}, 'DOI': '10.1016/j.chest.2020.06.082', 'type': 'journal-article', 'created': {'date-parts': [[2020, 7, 22]], 'date-time': '2020-07-22T15:16:06Z', 'timestamp': 1595430966000}, 'page': '108-111', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 61, 'title': 'The Minimal Effect of Zinc on the Survival of Hospitalized Patients With COVID-19', 'prefix': '10.1016', 'volume': '159', 'author': [ {'given': 'Jasper Seth', 'family': 'Yao', 'sequence': 'first', 'affiliation': []}, {'given': 'Joseph Alexander', 'family': 'Paguio', 'sequence': 'additional', 'affiliation': []}, {'given': 'Edward Christopher', 'family': 'Dee', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hanna Clementine', 'family': 'Tan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Achintya', 'family': 'Moulick', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carmelo', 'family': 'Milazzo', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jerry', 'family': 'Jurado', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nicolás', 'family': 'Della Penna', 'sequence': 'additional', 'affiliation': []}, {'given': 'Leo Anthony', 'family': 'Celi', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'issue': '1', 'key': '10.1016/j.chest.2020.06.082_bib2', 'first-page': '17', 'article-title': 'Zinc and respiratory tract infections: perspectives for COVID-19 ' '(review)', 'volume': '46', 'author': 'Skalny', 'year': '2020', 'journal-title': 'Int J Mol Med'}, { 'issue': '4', 'key': '10.1016/j.chest.2020.06.082_bib3', 'doi-asserted-by': 'crossref', 'first-page': '367', 'DOI': '10.1016/j.dsx.2020.04.015', 'article-title': 'Enhancing immunity in viral infections, with special emphasis on ' 'COVID-19: a review', 'volume': '14', 'author': 'Jayawardena', 'year': '2020', 'journal-title': 'Diabetes Metab Syndr Clin Res Rev'}, { 'key': '10.1016/j.chest.2020.06.082_bib4', 'doi-asserted-by': 'crossref', 'unstructured': 'Rahman MT, Idid SZ. Can Zn be a critical element in COVID-19 treatment ' '[published online ahead of print May 26, 2020]? Biol Trace Elem Res. ' 'https://doi.org/10.1007/s12011-020-02194-9', 'DOI': '10.1007/s12011-020-02194-9'}, { 'issue': '9', 'key': '10.1016/j.chest.2020.06.082_bib7', 'first-page': '768', 'article-title': 'Zinc: An essential micronutrient', 'volume': '79', 'author': 'Saper', 'year': '2009', 'journal-title': 'Am Fam Physician'}, {'key': '10.1016/j.chest.2020.06.082_bib8', 'author': 'Diaz'}, { 'issue': '20', 'key': '10.1016/j.chest.2020.06.082_bib9', 'doi-asserted-by': 'crossref', 'first-page': '2052', 'DOI': '10.1001/jama.2020.6775', 'article-title': 'Presenting characteristics, comorbidities, and outcomes among 5700 ' 'patients hospitalized with COVID-19 in the New York City area', 'volume': '323', 'author': 'Richardson', 'year': '2020', 'journal-title': 'JAMA'}, { 'issue': '1', 'key': '10.1016/j.chest.2020.06.082_bib10', 'doi-asserted-by': 'crossref', 'first-page': '22', 'DOI': '10.1513/AnnalsATS.201808-564PS', 'article-title': 'Control of confounding and reporting of results in causal inference ' 'studies', 'volume': '16', 'author': 'Lederer', 'year': '2019', 'journal-title': 'Ann Am Thorac Soc'}], 'container-title': 'Chest', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0012369220319619?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S0012369220319619?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2022, 7, 12]], 'date-time': '2022-07-12T00:30:29Z', 'timestamp': 1657585829000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0012369220319619'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 1]]}, 'references-count': 7, 'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2021, 1]]}}, 'alternative-id': ['S0012369220319619'], 'URL': 'http://dx.doi.org/10.1016/j.chest.2020.06.082', 'relation': {}, 'ISSN': ['0012-3692'], 'subject': [ 'Cardiology and Cardiovascular Medicine', 'Critical Care and Intensive Care Medicine', 'Pulmonary and Respiratory Medicine'], 'container-title-short': 'Chest', 'published': {'date-parts': [[2021, 1]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'The Minimal Effect of Zinc on the Survival of Hospitalized Patients With ' 'COVID-19', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Chest', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.chest.2020.06.082', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2020 American College of Chest Physicians. Published by Elsevier Inc. All ' 'rights reserved.', 'name': 'copyright', 'label': 'Copyright'}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit